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We report 4 cases of metastatic renal cell carcinoma (RCC) with long-term 
survival either following radical nephrectomy alone or in combination with radio- 
or hormonal therapy. 
Two patients with lymph node metastases showed a long-term survival of 12 
or more years following radical tumour nephrectomy (with lymphadenectomy) and 
radiotherapy. One of them exhibited a histologically proven tumour recurrence 
nearly 12 years after pIimary surgical treatment and died shortly later; the other 
one is still without any evidence of metastatic disease. 
Two other patients exhibited spontaneous regression of pulmonary metastases: 
one regression occurred after radical tumour nephrectomy alone, the other one after 
successful primary hormonal treatment a d subsequent radical tumour nephrectomy. 
The following important aspects are emphasized: 
1. Renal cell carcinoma is a very unpredictable tumour. Once the diagnosis 
of renal cell carcinoma is proved, a patient can never be considered cured. 
2. Although adjuvant palliative nephrectomy has produced contradictory 
results in several reports, radical tumour nephrectomy either alone or in combination 
with other adjuvant herapies such as r diotherapy, hormonal or immunological 
treatment, can be worthwhile. Cases with long-term survival and spontaneous regres- 
sion of distant metastases are proof of this. Besides, if carefully selected, the mortality 
rate of different adjuvant therapies i  not significantly higher in patients with meta- 
static disease than in patients without metastases. 
The world literature on this subject is reviewed. 
Introduction 
Renal cell carcinoma (RCC) is an aggressive, and unpredictable tumour. 
Symptoms quite often do not occur unti l  the tumour has already progressed 
quite far. At diagnosis about one third of all patients have already got distant 
metastases [16, 24], most commonly involving the lungs, liver, long bones and 
brain [16]. How to treat these patients has been the question for a number of 
decades. In the last 20 years treatment has consisted of radical nephrectomy 
either alone or combined with some sort of adjuvant herapy such as radio-, 
hormonal,  chemo- or most recently immunotherapy. All these therapies have 
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been tried with big hopes at first, but later have not lived up to expectations. 
So what is left is radical nephrectomy, sometimes in combination with one of 
the mentioned therapies, e.g. radiotherapy (Cases 1 and 2) or hormonal treatment 
(Case 4). 
Adjuvant palliative nephrectomy has produced contradictory results in 
several reports [15, 20, 21]. Their authors are not in favour of adjuvant nephrec- 
tomy as they have not observed spontaneous regression or long-term survival 
among their cases. Only Mires et al. [21] described one case of spontaneous 
regression of bone metastases in a group of 97 patients. At our Department, 
however, 4 cases (3.6~o) out of 110 with metastatic renal cell carciiloma (RCC) 
have shown this phenomenon following either radical turnout nephrectorny alone 
or in combination with an adjuvant therapy. Therefore our data correspond 
with the world literature in which the spontaneous regression rate of metastatic 
RCC ranges from 0.4 to 4~.  Two of our 4 cases have exhibited a long-term 
survival of 12 years or more in spite of histologically proven lymph node me- 
tastases (probably due to spontaneous regression), the other 2 have shown spon- 
taneous regression of pulmonary metastases [8]. So far most cases of spontaneous 
regression of metastatic RCC have been spontaneous regressions of pulmonary 
metastases following radical turnout nephrectomy. 
The following 4 cases are supporting the thesis that radical tumour nephrec- 
tomy - sometimes in combination with other adjuvant herapies - is worthwhile 
trying, whereas a therapeutical nihilism is not justified. 
Case reports 
Case 1. In October 1976, a 63-year-old woman had an accident in which 
she suffered fractures of the thoracic vertebrae VIii and XiI. In hospital routine 
laboratory investigations re,vealed polyglobulia with haemoglobin between 21 
and 22 ~ g/o- Subsequent bone marrow tap suggested polycythaemia vera. She 
was therefore transferred to the Medical Department for further investigation. 
A few days later she developed macrohaematuria that persisted for several days. 
IVU and abdominal ultrasound led to the suspicion of a solid mass in the lower 
pole of the left kidney. The patient was transferred to our Urological Department; 
here a CAT scan, cystoscopy and angiography confirmed the diagnosis of renal 
cell carcinoma (RCC) of the left lower pole. After a course of preoperative radio- 
therapy, left radical transperitoneal tumour nephrectomy was performed in 
December 1976. 
The removed kidney weighed 590 g and contained a large mass of 10 x 6 x 5 
cm in the lower pole with strong regressive alterations, scars and calcifications. 
Histology revealed clear cell renal cell carcinoma with ample necrosis and huge 
local lymph node metastasis. Postoperatively the patient made an uneventful 
recovery. 
At follow-up there was no evidence of relapsing tumour until May 1988. 
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At that time she developed a slowly progressive leg-accentuated flabby left 
hemiparesis n the course of several weeks; she also became temporarily confused. 
A CAT scan of her brain, taken as an out-patient several weeks prior to hospital 
admission revealed two hypodense lesions in the right parietal and frontal lobe 
that were enriched with contrast medium and surrounded by oedematous tissue. 
Both lesions were thought to be cerebral metastases of an unknown primary 
tumour. 
In August 1988 the patient was admitted to hospital for palliative treatment 
of cerebral metastases and diagnostic search for the primary tumour. On exam- 
ination, proximal and leg-accentuated flabby left hemiparesis and left hemi- 
dystaxia were found. Impairment of the vibration sensitivity of the left body half 
and left balance disorder were also diagnosed. The patient seemed to be mentally 
changed and inadequately euphoric. She was started on an anti-oedema treat- 
ment with steroids. At first her condition improved a bit. A second CAT scan 
of the brain showed a small diminution of the lesion in the parietal obe. 
A CAT scan of the thorax revealed two pulmonary lesions: one could be 
seen in the right lower field, the second, that was highly suspect of bronchial 
carcinoma, was fbund in the ventral part of the right lung near the aortic bend. 
As no other sign pointed towards another primary turnout, a primary bronchial 
carcinoma with cerebral metastases seemed most likely. Taking into consideration 
the border-compensated r nal insufficiency of the patient, a palliative treatment 
consisting of radiotherapy of the cerebral metastases was agreed on. Shortly 
after the start of radiotherapy her condition deteriorated rapidly; she died in 
September 1988, four months after the diagnosis of metastases of an unknown 
primary tumour had been established. A post-mortem revealed pulmonary and 
cerebral metastases of renal cell carcinoma (RCC), i.e. metastases of her former 
renal cell carcinoma of 1976. 
Case 2. In August 1977, a 68-year-old woman suffered from painless 
macrohaematuria. On clinical examination a palpable mass in the left flank 
was found, suspect of malignant renal tumour. A haemorrhage originating from 
the left ureteric ostium was endoscopically confirmed. Retrograde urogram showed 
a large space-occupying lesion in the middle and upper third of the left kidney. 
Renovasography and selective angiography confirmed the diagnosis of a huge, 
malignant left renal tumour. Cavography was without any evidence of avena  
cava tumour thrombus. 
After preoperative radiotherapy, left radical transperitoneal tumour neph- 
rectomy and splenectomy were performed in September 1977. 
Macroscopically a huge renal cell carcinoma of 7 x6 x4.5 cm was found 
that had invaded the renal pelvis and the venous system near the renal hilum. 
Another turnout near the renal hilum turned out to be a metastasis in a hilar 
lymph node. Histologically the tumour represented a clear cell renal cell car- 
cinoma with necroses and bleedings inside that invaded the venous system near 
the renal hilum and metastasized into hilar lymph nodes. The adrenal gland, 
the paraaortic lymph nodes and the spleen were free of turnout. 
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Postoperatively the patient made an uneventful recovery. However, as the 
tumour had spread to the hilar lymph nodes the patient received another adio- 
therapy of the left flank and the paraaortic lymph nodes about 3 weeks post- 
operatively, lasting 4 weeks. This was tolerated without any problems. 
So far the follow-up at regular intervals has not revealed any tumour 
recurrence. In December 1989 the patient has been without any evidence of 
relapsing tumour for more than 12 years. 
Case 3.* A 58-year-old woman was transferred to our Department in
September 1978, after she had been diagnosed at another hospital as having 
renal cell carcinoma of the left kidney with a solitary metastasis n the lower lobe 
of the right lung. In addition, renovasography was performed that clearly showed 
a huge malignant renal tumour in the upper pole of the left kidney. Cavography 
revealed a huge tumour thrombus in the renal vein. Preoperative chest X-ray 
confirmed the already mentioned pulmonary lesion in the right lower lobe (Fig. 1). 
As after an extensive diagnostic search (by bone and CAT scan) no other 
metastases had been found, it was decided - on consultation with the thoracic 
surgeons - to perform left radical tumour nephrectomy. The single pulmonary 
metastasis was scheduled for resection in a second operation. 
In October 1978, radical tumour nephrectomy combined with paraaortic 
lymphadenectomy was performed. Because of an excessive local tumour extension 
the spleen was also removed; intraoperatively it seemed that not every tumour- 
infected lymph node could be removed. The resected kidney was huge and macro- 
scopically contained a renal cell carcinoma (6 cm in diameter) in the upper pole 
that had invaded the renal capsule and the renal vein with moulding a tumour 
thrombus. Histologically the tumour turned out to be a clear cell renal cell car- 
cinoma that had infiltrated the renal capsule, the renal pelvis and the left adrenal 
gland and had spread to the hilar and paraaortic lymph nodes. 
On the sixth postoperative day the patient developed a left-sided pleural 
empyema. Postoperative chest X-ray now revealed - in contrast o the pre- 
operative one - an additional small right pulmonary metastasis just above the 
diaphragm (Fig. 2). Therefore, thoracotomy was cancelled. 
The pleural empyema was drained and dissolved quite quickly. As otherwise 
no complication occurred, the patient was released home on the 28th post- 
operative day. 
Due to a lack of convincing effects of chemo- and radiotherapy on renal 
cell carcinoma, the big tumour burden and the patient's devastating pro nosis, 
no adjuvant therapy was considered. However, follow-up at three-month intervals 
demonstrated an astonishing development: hree months postoperatively the 
* Cases 3 and 4 are being published in a case report in the British Journal of Urology 
in 1990 [8]. As the present paper is not only about long-term survival and late recurrence 
but also about spontaneous regression, and as all three topics undoubtedly belong together, 
the authors deem it necessary to include these two cases here in order not to falsify or change 
the tenor of the review. 
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Fig. 1. Case 3: Preoperative chest X-ray of a 58-year-old woman with a single pulmonary 
metastasis of the right lower lobe 
Fig, 2. Case 3 :20  days postoperatively a second pulmonary metastasis is clearly visible in 
the right phrenical angle 
patient had gained 1 kg in weight; the first pulmonary metastasis, which had 
been 3 cm in diameter, had shrinked to 1.5 cm in size, the smaller second metastasis 
had vanished. Another three months later the patient was in a good condition, 
had gained another 5 kg, and the first pulmonary metastasis hadalso disappeared. 
The patient even wanted to start work again. 
From October 1979 restaging was done half-yearly, from May 1983 yearly. 
In December 1989 the patient is still well and without any evidence of disease 
(Fig. 3). 
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Fig. 3a, b. Case 3: Actual chest X-ray, 11 years after tumour nephrectomy : no evidence of 
pulmonary metastases 
Case 4. In April 1984, a 45-year-old woman presented with permanent urge 
to cough. Chest X-ray revealed multiple metastases in both lungs (Fig. 4). Ab- 
dominal CAT scan revealed a left renal tnmour 6 cm in diameter with enlarged 
paraaortic lymph nodes (Fig. 5). 
According to this metastatic diagnosis, palliative hormonal treatment with 
the anti-oestrogen Tamoxifen (30 rag/day) for a period of 8 weeks was tarted 
in May 1984. 
In June 1984 a clinically fit patient without any pathological breathing or 
palpable abdominal tumour or lymph nodes presented at our hospital. Restaging 
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Fig. 4. Case 4: Preoperative chest X-ray of a 45-year-old woman: multiple pulmonary 
metastases on both sides 
Fig. 5. Case 4: CAT scan of the abdomen: solid masses in the upper pole of the right kidney, 
combined with enlarged retroperitoneal lymph nodes 
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revealed a nearly complete regression of metastatic disease: a CAT scan of the 
thorax showed three residual pulmonary metastases in the right upper zone and 
another one in the left lower zone; chest X-ray only revealed two residual metastases 
in the right mid-zone. Abdominal ultrasound showed a decrease in size of the 
formerly enlarged lymph nodes. Therefore, after further investigation by IVU, 
renovasography, cavography and bone-scan, left transperitoneal r dical turnout 
nephrectomy in combination with retroperitoneal lymphadenectomy was per- 
formed in July 1984. 
Macroscopically a tumour 6 cm in diameter was found that seemed to have 
infiltrated the renal capsule and pelvis. Histological examination revealed a high 
grade (G3) renal cell carcinoma with extensive necroses and cicatrization that 
had infiltrated the renal pelvis. The macroscopically visible infiltration of the 
renal capsule could not be confirmed histologically; however, here an extensive 
cicatrization with regressive alterations and older bleedings could be seen. The 
hilar and paraaortic lymph nodes that had been enlarged on the abdominal CAT 
scan were histologically without any live tumour cells. 
Postoperatively the patient made an uneventful recovery and was released 
home on the l lth postoperative day. She was kept on Tamoxifen 1 tablet t.d. 
(30 mg/day). 
At follow-up in December 1984 she had improved a lot, only three little 
pulmonary metastases were left that were only seen on thoracic CAT scan (on 
normal chest X-ray they were not visible). On follow-up she has remained free 
of disease until now (December 1989) under a therapy of 10 mg Tamoxifen per 
day (Fig. 6). 
Fig. 6. Case 4: Latest chest X-ray: still no evidence of recurrent metastatic disease 
(e.g. pulmonary metastases) 
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Discussion 
Spontaneous regression of cancer has been a subject in the world literature 
since the beginning of this century [23]. The first case of spontaneous regression 
of metastatic renal cell carcinoma was described by Bumpus in 1928 [5]. Until 
recently some authors have doubted its existence. Hcwexer, many authors ha~e 
proved that spontaneous regression can occur. The tumour with the second most 
reported spontaneous regressions is renal cell carcinoma (after malignant mela- 
noma) [26]. Katz and Schapira [16] e,~en put renal cell carcinoma (RCC) in 
first place followed by neuroblastoma, melanoma and choriccarcircn~a, in 
decreasing order of frequency. In 1977, Freed et al. [12] had collected 51 acceptable 
cases, inclusive 2 of their own. Only in one case had tlJmour regression occurred 
without nephrectomy, in two cases before nephrectomy and in 7 cases metastases 
occurred after nephrectomy and then regressed. In 4 cases regression occurred 
after nephrectomy and radiotherapy, in 45 cases spontaneous regression occurred 
in the lung, in only 6 cases had regression occurred elsewhere (3/cone, 1 intestines, 
1 skin, 1 thigh). Histologically proven metastases had been documented in only 
19 of the 51 cases, this is one third of all cases. Se~en of these cases had a follow-up 
of 2 years or less, and the remaining 12 cases had remissions lasting from 3 to 
21 years. Fairlamb [11 ] presents a similar list with 67 cases, the number of unre- 
ported cases may be much higher. The findings ef Freed et al. [12] exactly repro- 
duce Bloom's [1] definition of spontaneous regression: 
"Spontaneous regression is a partial or complete disappearance of a 
malignant tumour in the absence of all treatment, or in the l~resence of therapy, 
which is considered inadequate to exert a significant influence on ~eoplastic 
disease, and therefore we do not consider spontaneous regression synonymous 
with cure." 
One important question is: How often does spontaneous regression in 
metastatic renal cell carcinoma really occur? 
In an estimation made by Bloom in 1973 [2] there were 3 acceptable cases 
of regression in a series of llt30 hypernephroma p tients who had undergone 
nephrectomy (0.3 70). Other estimates vary from 0.4 to ] ~, this is 1 in 250 patients 
(0.470) [22]. Already in 1947 Hultquist emphasized [14] that many areas of 
cortical renal scarring represent regressing or obsolescent renal cell carcinoma 
and that these self-healing renal cell carcinomas have been noted in association 
with spontaneous disappearance of metastases. So the real incidence of spon- 
taneous regression should be much higher than 1 ~. 
Another important question is: How long can spontaneous regression be 
expected to last ? That spontaneous regression is not synonymous with cure has 
already been defined by Bloom [1 ] in 1964. Further clarification by Everson and 
Cole [10], in order to take account of the different developments of spontaneous 
regression in the world literature, reveals 6 distinct categories: 
1. regression of the primary tumour; 
2. regression of metastases with histologic onfirmation; 
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3. regression of metastases without histologic onfirmation; 
4. regression of presumptive metastases judged only radiologically; 
5. prolonged arrest; 
6. delayed metastases or recurrence. 
Bearing this clarification in mind, all of our 4 cases belong to at least one of 
the six categories and can therefore be called spontaneous regressions. 
The last two categories are of particular interest o the urologist, as the 
biological activity of many genitourinary cancers, especially renal cell carcinoma, 
is notoriously unpredictable [16]. Not uncommonly, patients have delayed meta- 
static lesions from hypernephroma several years after a presumably curative 
nephrectomy. Our first case is a typical example. Here, more than 11 years after 
nephrectomy multiple metastases occurred in the brain and the lungs and the 
patient died 4 months after diagnosis. Other examples can be found in the litera- 
ture [2, 9, 19, 28]. The questions are: What accounts for this variation in tumour 
activity? is there a change in the tumour cells themselves causing increased 
virulence or is there a sudden breakdown in the host environment, permitting 
uncontrolled growth of tumour cells previously held in check? [16] 
The last and probably most important question is: Why does spontaneous 
regression occur and where does it most commonly take place ? 
Although the concept of spontaneous regression of clinical cancer is tenable, 
the factors responsible for its occurrence remain conjectural. Aetiologic factors 
thought to be involved in spontaneous tumour egression i clude: 
(a) host "walling-off" mechanisms with self healing; 
(b) hormonally included changes; 
(c) trauma (for example major surgery); 
(d) infections and/or fever; 
(e) alterations of the immune status [16]. 
Interesting is that 3 of these factors, that is infection, hormonally induced changes 
and altered immune status, appear to be present in the majority of reported 
cases. Indeed, Stephenson et al. [27] demonstrated _>1 of these 3 factors in 184 
(82 ~) of their 224 patients. 
Of particular interest in our case are the hormonally induced changes. Two 
different aspects play a role here of which one aspect is especially important 
because it has therapeutic consequences. The sex incidence of renal cell cancer 
is divided evenly between male and female patients -<45 years old. However, 
after menopause the relative female incidence decreases harply so that the fre- 
quency in male patients becomes 2 to 3 times higher. The 5-year survival rate 
after nephrectomy is twice as great for men as for women. Although the range 
of ages for reported cases of spontaneous regression favours this postmenopausal 
group, the proportion of male patients demonstrating this phenomenon is dispro- 
portionately high (70 ~) [16!. Therefore the clinical effectiveness of progestational 
agents and androgens in treating patients with renal cell cancer has been studied 
extensively. Although initial reports on success with this mode of therapy quoted 
objective responses in approximatel 3, 16 per cent of the treated patients [3], 
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subsequent studies have failed to support these claims. Recent reports on the 
effectiveness of progestagens in cases of renal cell cancer show no statistical 
difference in survival between treated and untreated patients [4]. However, in 
our case the patient was started on hormonal therapy with the anti-oestrogen 
Tamoxifen, because her illness was too advanced to consider nephrectomy. 
Within a few weeks her pulmonary metastases had resolved as stated by Bloom [2]. 
After subsequent nephrectomy and continuous treatment with Tamoxifen 10 
rag/day she has now remained free of disease for nearly 5 years. A similar case 
is reported by Kavoussi et al. [17], other positive cases by Bloom [3]. Therefore, 
there is a big chance that the presence or lack of oestrogen or progesterone 
receptors may predict a response to anti-oestrogen or progesterone therapy [26]. 
Interesting is that in most cases of spontaneous regression adjuvant radical 
nephrectomy had been performed before regression occurred. There are two 
hypotheses for this finding, both of them of immunological background: 
1. Attempts at resection can disseminate tumour cells into blood vessels 
or lymphatics. This cell dissemination might result in a large turnout antigen 
load and perhaps timulate a strong host antitumour response. 
2. Simple debulking is the second possibility. The explanation might be
that the antigen load of the primary turnout is too big for the body's immune 
system to be able to react. So nephrectomy would remove most of the antigen 
load and thus allow better use of the effector arms of the immune system [16]. 
Therefore most authors are in favour of nephrectomy [11, 13, 18, 19], 
especially if there is only a single metastasis [7, 17, 18]. Garfield [13] defines the 
role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma 
as follows: 
(i) nephrectomy may eliminate or prevent he source of fever and toxicity 
due to the primary tumour; 
(ii) it may reverse hepatopathy; 
(iii) secondary anaemia or erythrocytosis related to erythropoietin over- 
production can be corrected; 
(iv) removal of a large primary tumour may eliminate the source of pain 
and a potential source of haematuria; 
(v) hypercalcaemia c n be corrected; 
(vi) removal of a large bulk of tulnour eliminates the major source of 
a parathormone-like polypeptide; 
(vii) an important factor, although rare, is the disappearance of metastases. 
A final point is that in patients with histologically proven metastatic disease 
in the lymph nodes survival can be prolonged for a long time after nephrectomy, 
i.e. debulking, as our first three cases show. Without nephrectomy 80-90~ 
of the patients with metastatic disease in the lymph nodes are dying within a year 
of diagnosis (.follow-up of patients with lymph node metastases at our Depart- 
ment). 
However, in recent years there have been voices against adjunctive nephrec- 
tomy [15, 20, 21, 22]. Since the incidence of regression of metastases had been 
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less than 1%, Middleton [20] calculated that the morbidity and mortality from 
nephrectomy in these patients are higher than the potential benefit and therefore 
concluded that nephrectomy for the sole purpose of achieving regression of 
metastases is not warranted in asymptomatic patients. The rnortality ofadjunctive 
nephrectomy under these circumstances ranges from 2 to 15%; most of the 
authors report 5% [6, 22, 25]. 
However, as the mortality is not much higher than in patients without 
metastases, if the patients are carefully selected we advocate adjunctive nephrec- 
tomy. Nevertheless, we think that if ever possible additional adjuvant herapy 
should be given, such as the application of biological response modifiers (e.g. 
interferons), with which the rate of spontaneous remissions can reach more than 
20%. Interesting in this context is that there seems to be an organ specificity in 
the ability to cope with metastases [13, 16]. Out of 39 reported cases 37 repre- 
sented regression of pulmonary metastases, and in some instances there was 
simultaneous regression of pulmonary metastases with progression of non- 
pulmonary metastases, e.g. in the bones or brain [13]. An explanation may be 
that pulmonary tissue, probably caused by constant exposure to foreign antigens, 
is especially rich in macrophages, lymphocytes and immunoglobulin lgA (immu- 
nological hypothesis) [16]. 
However, it is at present unknown which sort of adjuvant immunotherapy 
is best, despite xtensive scientific research. We think that under the mentioned 
circumstances a therapeutic nihilism is not justified. In case of metastatic RCC 
we advocate radical tumour nephrectomy followed by an adjuvant therapy with 
interferons alone or in combination with interleukin-II. 
Nevertheless, one has got to bear in mind what Montie and associates 
write: "The psychologic pressure imposed on a surgeon to perform an ablative 
procedure occasionally can be overwhelming. The desire by the physician and 
patient o do something must be judged in light of potential benefits from the 
operation and the operative mortality and morbidity. The psychological benefits 
may justify the risk undertaken but this should be recognized as such by the 
involved medical team" [22]. 
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